BioCentury | Jan 8, 2019
Distillery Therapeutics

Transplant

...CORO1A knockout or a PDE-4 inhibitor tool compound increased skin allograft survival compared with normal CORO1A...
...in Phase II/III testing for Crohn's disease and Phase II testing for COPD. TARGET/MARKER/PATHWAY: Coronin-1A (CORO1A...
...Switzerland email: rajesh.jayachandran@unibas.ch CONTACT: Jean Pieters, same affiliation as above email: jean.pieters@unibas.ch Claire Quang University of Basel Coronin-1A (CORO1A) Phosphodiesterase-4...
BioCentury | Feb 7, 2008
Distillery Therapeutics

This Week in Therapeutics

...therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune Systemic lupus erythematosus (SLE) Coronin-1A...
...strategy for treating SLE. Coronins are actin-associated cytoskeletal proteins, and a single mutation in the coronin-1A...
BioCentury | Aug 24, 1998
Clinical News

ReoPro abciximab GPIIb/IIIa platelet inhibitor: Phase III data; marketed to reduce acute ischemic cardiac complications in patients undergoing percutaneous coro

CNTO presented six-month follow-up data showing a sustained long-term benefit in its 2,399-patient EPISTENT Phase III trial comparing ReoPro plus stents or ReoPro plus angioplasty to stent placement alone. Positive results from the 30-day primary...
Items per page:
1 - 3 of 3